The SARS-CoV-2 virus global outbreak generated a need for fast and reliable large-scale testing to diagnose and prevent further COVID-19 transmission. One of the main bottlenecks of the PCR test was the laborious and time-consuming molecular method for viral genetic material extraction. As a solution, BioEcho developed a novel and rapid multi-well extraction protocol for viral RNA and DNA that reduces the isolation of SARS-CoV-2 nucleic acids to just a few minutes per 96 samples.
SARS-CoV-2 RNA extraction in just 2 minutes
BioEcho’s patent-pending technology is based on a single-step nucleic acid extraction method and differs from the products available on the market, which are established on a silica column that follows the bind-wash-elute principle. The cutting-edge BioEcho technology increases the throughput by reducing the time for viral genetic material extraction procedure to 2 minutes following sample preparation. Speeding up this step more than 20-fold over other extraction technologies leads to thousands of tests on COVID-19 easily achievable per day.
Agile solutions for molecular diagnostics
BioEcho’s pioneering product, EchoLUTION for viral RNA and DNA extraction 48-well or 96-well kit, has been validated by multiple diagnostic laboratories for SARS-CoV-2 detection from nasopharyngeal samples. All could significantly increase their test-throughput up to many thousands per day. BioEcho’s viral nucleic acids extraction products already cover almost 12% COVID-19 PCR tests performed in Germany and estimated 50% in Austria. Currently, BioEcho is working towards implementing precise, reproducible, and rapid, automated solutions, as well as developing new technologies for the detection of numerous pathogens.
SARS-CoV-2 RNA extraction in just 2 minutes
BioEcho’s patent-pending technology is based on a single-step nucleic acid extraction method and differs from the products available on the market, which are established on a silica column that follows the bind-wash-elute principle. The cutting-edge BioEcho technology increases the throughput by reducing the time for viral genetic material extraction procedure to 2 minutes following sample preparation. Speeding up this step more than 20-fold over other extraction technologies leads to thousands of tests on COVID-19 easily achievable per day.
Agile solutions for molecular diagnostics
BioEcho’s pioneering product, EchoLUTION for viral RNA and DNA extraction 48-well or 96-well kit, has been validated by multiple diagnostic laboratories for SARS-CoV-2 detection from nasopharyngeal samples. All could significantly increase their test-throughput up to many thousands per day. BioEcho’s viral nucleic acids extraction products already cover almost 12% COVID-19 PCR tests performed in Germany and estimated 50% in Austria. Currently, BioEcho is working towards implementing precise, reproducible, and rapid, automated solutions, as well as developing new technologies for the detection of numerous pathogens.
